Federica Pecci: The Optimal 1L Treatment for Patients with MET Exon 14 Skipping NSCLC
Federica Pecci, Research Fellow of Thoracic Oncology at Dana-Farber Cancer Institute, shared a post on X about a paper she co-authored with colleagues published in Clinical Cancer Research:
“Finally, published in Clinical Cancer Research, our multicenter study on the optimal first-line treatment for patients with MET exon 14 skipping NSCLC.
In the overall population, first-line MET TKI led to a higher objective response rate, but no significant differences in real-world PFS or OS were observed compared to ICI ± chemotherapy.
Subgroup analyses indicate that patients with tumors expressing PD-L1 <50% or with baseline brain or bone metastases may experience greater benefit from first-line MET TKI.
Only those patients with tumors exhibiting very high PD-L1 expression (≥80%) appear to derive greater benefit from first-line ICI ± chemotherapy.
Safety profile was comparable between first-line MET TKI and ICI ± chemotherapy in terms of high grade toxicity and permanent discontinuation.
Our study highlights the need for harmonized reimbursement policies to ensure access to MET TKIs (capmatinib/tepotinib) as first-line therapy in METex14 NSCLC and supports personalized strategies guided by baseline clinicopathologic factors to improve clinical outcomes.
Thanks to all the coauthors for making this work possible.”
Title: First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Authors: Federica Pecci, Hui Li, Alessandro Di Federico, Jia Wu, Hong Chen, Eleonora Gariazzo, Francesco Mantuano, Edoardo Garbo, Mihaela Aldea, Valentina Santo, Don Gibbons, Hai Tran, Francesco Paoloni, Guilherme Rossato de Almeida, Giulio Metro, Andrea De Giglio, Francesco Gelsomino, Xinan Wang, Marcello Tiseo, Julia Rotow, Andrea Ardizzoni, J. Jack Lee, Mark M. Awad, Alfredo Addeo, Lingzhi Hong, Marcelo V. Negrao, Pasi A. Janne, John V. Heymach, Jianjun Zhang, Biagio Ricciuti, Xiuning Le
You can read the Full Article in Clinical Cancer Research.
More posts featuring Federica Pecci.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023